The Royal Society of Medicine

Journal of the Royal Society of Medicine; 2015, Vol. 108(11) 440–450
DOI: 10.1177/0141076815593403

Statistical analyses in Swedish randomised trials on mammography screening and in other randomised trials on cancer screening: a systematic review

Philippe Autier[1,2], Mathieu Boniol[1,2], Michel Smans[2], Richard Sullivan[3] and Peter Boyle[1,2]
[1]Institute of Global Public Health at iPRI, International Prevention Research Institute, University of Strathclyde, Ecully Lyon 69130, France
[2]International Prevention Research Institute (iPRI), Lyon 69006, France
[3]Institute of Cancer Policy, Kings Health Partners Cancer Centre, London SE1 9RT, UK
Corresponding author: Philippe Autier. Email: philippe.autier@i-pri.org

Abstract

Objectives: We compared calculations of relative risks of cancer death in Swedish mammography trials and in other cancer screening trials.
Participants: Men and women from 30 to 74 years of age.
Setting: Randomised trials on cancer screening.
Design: For each trial, we identified the intervention period, when screening was offered to screening groups and not to control groups, and the post-intervention period, when screening (or absence of screening) was the same in screening and control groups. We then examined which cancer deaths had been used for the computation of relative risk of cancer death.
Main outcome measures: Relative risk of cancer death.
Results: In 17 non-breast screening trials, deaths due to cancers diagnosed during the intervention and post-intervention periods were used for relative risk calculations. In the five Swedish trials, relative risk calculations used deaths due to breast cancers found during intervention periods, but deaths due to breast cancer found at first screening of control groups were added to these groups. After reallocation of the added breast cancer deaths to post-intervention periods of control groups, relative risks of 0.86 (0.76; 0.97) were obtained for cancers found during intervention periods and 0.83 (0.71; 0.97) for cancers found during post-intervention periods, indicating constant reduction in the risk of breast cancer death during follow-up, irrespective of screening.
Conclusions: The use of unconventional statistical methods in Swedish trials has led to overestimation of risk reduction in breast cancer death attributable to mammography screening. The constant risk reduction observed in screening groups was probably due to the trial design that optimised awareness and medical management of women allocated to screening groups.

Keywords

breast cancer, screening, randomised trials, statistical analyses

Introduction

Between 1977 and 1996, five randomised trials on mammography screening were conducted in Sweden. An overview of these trials published in 2002 reported that two to four rounds of mammography screening could decrease breast cancer risk by 21%.[1]

Mammography screening works through finding non-clinically detectable breast cancer before progression into advanced cancer with metastatic spread in lymph nodes and distant organs. Since reduction in cancer deaths due to reduction in the incidence of advanced cancer is not influenced by treatment efficacy, it was concluded from Swedish trials that decreases in the incidence of advanced breast cancer after screening introduction would provide the best indication that mammography screening reduces breast cancer mortality.[2]

However, in communities where screening participation was high for more than 10 years, only modest or no declines in the incidence of advanced breast cancer were observed.[3–5] This situation is in sharp contrast with that of colorectal and cervical cancer screening, because in communities where screening for cervical and colorectal cancers is widespread, marked declines in the incidence of these types of cancers at an advanced stage have been observed, which indicates a substantial contribution of these screening modalities.[6,7]

Breast screening trials were initiated at a time when there was limited experience for designing, conducting and analysing cancer screening trials. We therefore postulate that the contrasts between breast and cervical or colorectal cancers could be due to differences in the way randomised trials were conducted and analysed. In this study, we re-examine

© The Royal Society of Medicine 2015
Reprints and permissions: sagepub.co.uk/journalsPermissions.nav

the mortality data used and the way risks of breast cancer death were computed in Swedish trials in the light of study design and statistical analyses performed in screening trials on cancers other than breast cancer.

Designs of randomised trials for the evaluation of cancer screening tests

These trials are typically composed of two successive periods (Figure 1(a)): the intervention period that extends from randomisation to termination of the last screening round in the screening group, and the post-intervention period that extends from the end of the last screening round in the screening group to the date of last check of vital status of subjects that were included in the trial. The follow-up period is the total of the intervention and the post-intervention periods. Depending on the number of screening rounds and follow-up extent, intervention and post-intervention periods may be of variable duration. Randomised trials evaluating cancer screening methods may consist of a single intervention of short duration including invitation to screening, the screening test itself and possible work-up procedures in case of suspicious screening result. In other trials, the intervention period lasts for several years because the screening test is repeated every year or every two years. After the last screening round in the screening group, screening may be interrupted. Alternatively, screening may be pursued in the screening group and implemented in the control group, when, for instance, decision is taken to launch a population screening program.

Relative risks of cancer death associated with screening are computed by dividing the cancer death rate in the screening group by the cancer death rate in the control group (Box 1). Cancer death rates can be calculated using deaths due to cancers found during the follow-up period as numerator (follow-up method), or using deaths due to cancers found during the intervention period as numerator (evaluation method). Denominators are the same in both methods. If in a trial, there is no post-intervention period, then the evaluation and follow-up periods coincide. During post-intervention periods, because screening (or absence of screening) activities are similar in the screening and in the control group, cancer detection rates in the two groups (i.e. Dsp/Ns and Dcp/Nc in Box 1) are also similar. In the follow-up method, growing numbers of deaths due to cancers found during steadily longer post-intervention periods will progressively narrow (or dilute) the difference in cancer death rates between the two groups. In this regard, reduction in the risk of cancer death calculated according to the follow-up method may be smaller than when calculated according to the evaluation method. For instance, in the fecal-occult-blood-test trial in England, the relative risk of colorectal cancer death after 7.7 years of follow-up (6.7 years

Figure 1. Design of randomised trials for the evaluation of cancer screening methods (R: screening round). Intervention periods are the continuous lines and the post-intervention periods are the dashed lines. (a) Typical design, (b) design specific to Swedish trials on breast cancer screening.



Box 1. Computation of relative risk (RR) of cancer death in randomised trials on cancer screening.

For the screening group: D_{SI} is the number of cancer deaths related to cancers found during the intervention period, D_{SP} is the number of cancer deaths related to cancers found during the post-intervention period and N_S is the number of subjects included in the screening group.
For the control group: D_{CI} is the number of cancer deaths related to cancers found during the intervention period, D_{CP} is the number of cancer deaths related to cancers found during the post-intervention period and N_C is the number of subjects included in the control group.
Computations of RR of cancer death are:
Evaluation method: $RR_{EM} = (D_{SI}/N_S)/(D_{CI}/N_C)$
Follow-up method: $RR_{FUM} = [(D_{SI} + D_{SP})/N_S]/(D_{CI} + D_{CP})/N_C]$
Note: Numbers of person-years of follow-up (i.e. years spent by each subject in the trial) may be used instead of numbers of subjects. The two types of denominators provide similar results because in trials, duration of follow-up of subjects in screening and in control groups is the same.

of intervention and 1 year of post-intervention) was 0.85 (95% CI: 0.74; 0.94) and 0.91 (95% CI: 0.84; 0.98) after 20 years of follow-up (6.7 years of intervention and 13.3 years of post-intervention).[8]

Cause of death assessment and statistical analysis in trials on screening for cancer other than breast cancer

We retrieved publications on 17 cancer screening trials other than breast cancer in which main trial results were presented (see eTable in the Supplement). In 14 trials, cause of death assessment was done by committees unaware of the screening status of subjects that decided on likely causes of death using all available information. In all 17 trials, the relative risk of cancer-specific death associated with screening was calculated using deaths due to target cancers found during follow-up periods (follow-up method).

Cause of death assessment and statistical analysis in breast cancer screening trials

Committees for cause of death assessment independent of trial conduct and blinded as to the screening status of deceased women were implemented in the Health Insurance Plan[9] and in the Canadian trials[10] (Table 1). The Two-County trial used causes of death established by local endpoint committees or a Joint Review Committee, both of which included trial investigators.[11] Swedish trials included in the overview of 2002 and in the Age trial used causes of death reported on death certificates.[1,12]

All breast screening trials calculated relative risks of breast cancer death associated with screening using deaths due to breast cancers found during the intervention period of the screening and of the control groups (Evaluation method) (Table 1). However, the Swedish trials and their overview used a different selection of breast cancer deaths for control groups, as one sentence in the statistical section of the 2002 overview makes clear, 'The evaluation [method] ignores breast cancer deaths among women whose breast cancer diagnosis was made after the first screening round of the control group was completed'.[1] This means that the breast cancer deaths in the control group that were used for calculating the relative risk included breast cancer deaths related to cancer cases found at first screening of this group (R_{C1} in Figure 1(b)). This first screening of the control group generally took place in years following the last screening round in the screening group.[13–16] Hence, if screening of the control group had not taken place, these cancers would have been diagnosed during the post-intervention period. This incorporation approach was thus equivalent to transferring to the intervention period a number of cancers and associated deaths that were part of the post-intervention period. It is important to note that this approach was applied to the control group only. As a consequence, publications reported more cancers per women in control groups than per women in screening groups.[16–18] Translating this incorporation approach in equations displayed in Box 1 gives:

$RR_{EM/ST} = (D_{SI}/N_S)/[(D_{CI} + D_{RC1})/N_C]$, where $RR_{EM/ST}$ stands for the evaluation method specific to Swedish trials. D_{RC1} are deaths due to breast cancers found at first screening of the control group that pertain to the post-intervention period, (i.e. D_{CP} in Box 1) and not to the intervention period, (i.e. D_{CI} in Box 1).

The Two-County and the Stockholm trials reported numbers and stage of cancers found at first screening of control groups, showing that the incorporation approach resulted in adding 72 advanced (i.e. 20 mm size or more) cancers to the 434 advanced cancers diagnosed in the control

Table 1. Data used for relative risks calculation in randomised trials on breast cancer screening.

Trial no.	First author, year of publication*	Country, study acronym	Screening method (as compared to the control group)	Follow-up period (years)		Cause of death assessment	Cancer-specific deaths used for calculation of the main relative risk associated with screening	RR	95% CI
				Intervention period	Post-intervention period				
1	Shapiro et al., 1997[26]	USA, Greater New York Health Insurance Plan	MMS + BCE every 12 months, 4 rounds	5	13	Committee unaware of screening status	Cancer-specific deaths of cancers found during the intervention period	0.77	NR
2	Tabar et al., 2011[20]	Sweden, Two-County trial†	MMS, 2–4 rounds	7	22	Local committee	Cancer-specific deaths of cancers found during the intervention period plus, for the control group, incorporation of cancer-specific deaths of cancers found at first screening of this group	0.69	0.56; 0.85
	id.	id.	id.	id.	id.	Joint review committee‡	Cancer-specific deaths of cancers found during the intervention period plus, for the control group, incorporation of cancer-specific deaths of cancers found at first screening of this group	0.73	0.59; 0.89
2	Nyström et al.	Sweden, Ostergotland§	MMS, 2–4 rounds	7.7	9.7	Death certificates	Cancer-specific deaths of cancers found during the intervention period plus, for the control group, incorporation of cancer-specific deaths of cancers found at first screening of this group	0.90	0.73; 1.11

(continued)

Table 1. Continued.

Trial no.	First author, year of publication*	Country, study acronym	Screening method (as compared to the control group)	Follow-up period (years)		Cause of death assessment	Cancer-specific deaths used for calculation of the main relative risk associated with screening	RR	95% CI
				Intervention period	Post-intervention period				
3	Nyström et al.[1]	Sweden, Malmö I	MMS every 18–24 months, 6–8 rounds	15	5	Death certificates	Cancer-specific deaths of cancers found during the intervention period plus, for the control group, incorporation of cancer-specific deaths of cancers found at first screening of this group	0.82	0.67; 1.00
4	Nyström et al.[1]	Sweden, Malmö II	MMS every 18–24 months, 1–7 rounds	5.8	3.3	Death certificates	Cancer-specific deaths of cancers found during the intervention period plus, for the control group, incorporation of cancer-specific deaths of cancers found at first screening of this group	0.64	0.39; 1.06
5	Nyström et al.[1]	Sweden, Stockholm	MMS every 24–28 months, 2 rounds	4.4	10.5	Death certificates	Cancer-specific deaths of cancers found during the intervention period plus, for the control group, incorporation of cancer-specific deaths of cancers found at first screening of this group	0.91	0.65; 1.27
6	Nyström et al.[1]	Sweden, Göteborg	MMS, 3–5 rounds	7 (women 39–49) and 5 (women 50–59)	7 (women 39–49) and 9 (women 50–59)	Death certificates	Cancer-specific deaths of cancers found during the intervention period plus, for the control group, incorporation of cancer-specific deaths of cancers found at first screening of this group	0.76	0.56; 1.04

(continued)

Table 1. Continued.

Trial no.	First author, year of publication*	Country, study acronym	Screening method (as compared to the control group)	Follow-up period (years)		Cause of death assessment	Cancer-specific deaths used for calculation of the main relative risk associated with screening	RR	95% CI
				Intervention period	Post-intervention period				
7	Miller et al., 2014[22]	Canada, NBSS I and II	MMS every year, 4–5 rounds	5	20	Committee unaware of screening status	Cancer-specific deaths of cancers found during the intervention period	1.05	0.85; 1.30
8	Moss et al., 2006[12]	England, Age trial	MMS every 12 months, 4–6 rounds	5	6	Death certificates	Cancer-specific deaths of cancers found during the intervention period	0.83	0.66; 1.04

BCE: Breast physical examination; MMS: Mammography screening; RR: Relative risk; NBSS: National Breast Screening Study.
*The most recent publication reporting on main trial results is displayed in the Table.
†This trial was done in the counties of Dalarna (formerly Kopparberg) and Ostergötland.
‡The Joint Review Committee included Two-County trial investigators (Holmberg et al., 2009[11]) and has to be distinguished from the Independent Endpoint Committee set up by Swedish trial overviews (Nyström et al., 1993)[29]
§The Ostergötland county trial was part of the Two-County trial, but results specific to the Ostergötland trial were published in Nyström et al.[1]

group during the intervention period of the Two-County trial[13] and 30 advanced cancers (i.e. stage 2 or more) to the 173 advanced cancers diagnosed in the control group during the intervention period of the Stockholm trial.[19] Because of their high fatality rate, these extra advanced cancers led to a substantial number of extra cancer deaths, i.e. D_{RC1}. Thus, the greater the value of D_{RC1}, the smaller the value of $RR_{EM/ST}$ and thus the greater the apparent reduction in the risk of breast cancer death associated with mammography screening.

Alternative calculation of results of Swedish trials

We estimated a relative risk according to the evaluation method that would not incorporate deaths due to cancers found at first screening of control groups, that is, we estimated D_{CI} and D_{RC1} of the $RR_{EM/ST}$ equation. In Swedish trials, the ratio between breast cancer mortality rates in the screening and control groups remained relatively equivalent after 10–12 years of follow-up.[1,20] Furthermore, the Two-County trial reported that after 29 years of follow-up, 10% of breast cancer deaths in the control group were associated with cancers found during the first screening of control women.[20] The 10% figure is plausible because follow-up of the additional cancers was shorter than for cancers found during intervention periods. We thus inferred that 10% represented a valid estimate of the proportion of extra deaths added to intervention periods of control groups in the overview of 2002.

The evaluation method specific to Swedish trials found a relative risk of 0.79, while the follow-up method found a relative risk of 0.85, reflecting dilution of effect over time (Table 2).

In the central column of Table 3, we estimated breast cancer deaths linked to cases found at first screening of control women by multiplying by 10% the number of breast cancer deaths in control groups of the Östergötland, Goteborg and Stockholm trials. We set the estimate to 4.5% for Malmö I because first screening of control group concerned about 45% of the total number of control women included in the trial.[21] In Malmö II, we set estimates to 7.5% because the follow-up period lasted 9.1 years.[1] We obtained an estimate of 46 breast cancer deaths related to breast cancers found at first screening of control groups. In the two right-hand columns, we reallocated to post-intervention periods the 46 breast cancer deaths associated with cases found during first screening of control groups.

We then reworked results of the overview of 2002[22] in Table 2 using numbers of breast cancer deaths in control groups we estimated in Table 3. The relative risk of breast cancer death over the follow-up period remained unchanged, but the relative risk of breast cancer death for the evaluation method was 0.86 instead of 0.79. For breast cancers diagnosed during the post-intervention period, the relative risk of breast cancer death dropped to 0.83. Sensitivity analysis using 8% or 12% for reworking numbers of breast cancer deaths in control groups of the Östergötland, Goteborg and Stockholm trials did not change the corrected relative risk estimates much (data not shown).

So, proper allocation of breast cancer deaths to the intervention and post-intervention periods led to an equalisation of relative risks found for the intervention, post-intervention and follow-up periods, with a risk of breast cancer death that remained about 15% lower in the screening group throughout the entire trial duration.

Discussion

Computations performed by the overview of Swedish mammography trials incorporated deaths of breast cancers found at first screening of the control group as if these cancers were part of intervention periods.[1] The consequence of this incorporation approach was the overestimation of rates of breast cancer death in the control groups, which ended up in the overestimation of the protection conferred by mammography screening against breast cancer death. Other authors raised similar concerns, estimating that the evaluation method adopted by Swedish trials resulted in including in the control groups many cancers that would not have been found in the screening group, which biased results in favour of screening.[23]

Non-Swedish breast screening trials and trials on screening for cancer other than breast cancer never used the incorporation approach, and we found practically no methodological justification for this approach. The Goteborg trial investigators argued that there was a need to compensate for the extra number of cancer found by screening that are included for follow-up to death in the screening group.[16,24] However all extra screen-detected invasive cancers in screening groups were early cancers, i.e. tumours less than 20 mm in diameter or stage 1.[13,17,19,25] Hence, the conceivable need to compensate for screen detection of extra numbers of early cancer could not justify the transfer to intervention periods of substantial numbers of advanced cancers found at first screening of control groups. Substantial numbers of extra cancers were also found in screening groups of trials of prostate and lung cancer. However, none of these trials resorted to screening

Table 2. Breast cancer deaths in the Swedish trials included in the 2002 overview.*

Group	No. women 40–74 included in trials†	Person-years of follow-up (thousand)‡	No. of BC deaths related to:			RR (95% CI) of BC death for BCs detected:		
			BC found during the intervention period	BC found during the post-intervention period	BC found during the follow-up period	During the intervention period (evaluation model)§	During the post-intervention period§	During the follow-up period (follow-up model)§
			As reported in the overview					
Screening	129750	1865	511	284	795	0.79	0.98	0.85
Control	117260	1688	584	263	847	(0.70; 0.89)	(0.83; 1.15)	(0.77; 0.94)
			After reallocation to the post-intervention period of 10% breast cancer deaths found at first screening of the control group**					
Screening	129750	1865	511	284	795	0.86	0.83	0.85
Control	117260	1688	538	309	847	(0.76; 0.97)	(0.71; 0.97)	(0.77; 0.94)

BC: Breast cancer; RR: Relative risk.
*Nyström et al.[1]; trials included in the overview are listed in Table 3.
†Data from Table 2 of Nyström et al.[1]
‡Data from Table 4 of Nyström et al.[1]
§RR computed using No. of women 40–74 as denominator.
**Table 3 for computation of BC deaths in the control group.

Table 3. Breast cancer deaths in Swedish mammography trials.

Breast cancer deaths of:	Screening group*	Control group*	BC deaths of BCs found at first screening of the control group (10% hypothesis†)	Reallocation of BC deaths found at first screening of the control group	Corrected numbers of BC deaths in control groups
BC found during intervention periods					
Malmö I	161	198	9	198 − 9 =	189
Malmö II	29	33	2	33 − 2 =	31
Ostergötland	177	190	19	190 − 19 =	171
Stockholm	82	50	5	50 − 5 =	45
Göteborg	62	113	11	113 − 11 =	102
All five trials	**511**	**584**	**46**	**584 − 46 =**	**538**
BC found during post-intervention periods‡	**284**	**263**		**263 + 46 =**	**309**
BC found during follow-up periods	**795**	**847**			**847**

BC: Breast cancer.
*From Table 4 of Nyström et al.[1]
†For Malmö I, the hypothesis was 4.5% and for Malmö II, the hypothesis was 7.5%.
‡Number of BCs in each trial during the post-intervention period were not provided.

the control group after termination of the intervention and to transfer these cancers to the intervention period. The compensation argument invoked by Swedish trial investigators[16,24] is thus not tenable.

Our re-calculations of Swedish trial revealed that risks of breast cancer death were similar for cancers found during the intervention and the post-intervention periods, indicating that reductions in the risk of breast cancer death also applied to cancer cases diagnosed when screening (or absence of screening) was the same in both screening and control groups. Such result is compatible with an effect of being allocated to the screening or to the control group on the risk of breast cancer death (allocation effect), but not with an effect of mammography screening (screening effect) on that risk.

Two reasons could explain a lower risk of breast cancer deaths independent of mammography screening. First, the Health Insurance Plan,[26] Age[12] and all Swedish trials[1,16,18,20,25,27] that found decreased risk of breast cancer death associated with mammography screening adopted a 'left-to-nature' design. Typically, parallel group randomised trials first recruit a group of eligible subjects that are informed on trial objectives, on potential health benefits and probable side effects. Subjects agreeing to participate must first sign an informed consent form after which they are randomised in an intervention or in a control group. In left-to-nature trials, only women invited to participate in breast screening knew they were part of a clinical trial. Women allocated to control groups were never contacted, did not sign an informed consent and were completely ignorant they were part of a trial. Health professionals knew or could detect which women were invited to screening but did not know which women were allocated to control groups. Imbalance between the two groups probably led to increased awareness and better information (e.g. on early breast symptoms) and medical management of women in screening groups. Women invited to screening probably had quicker access to specialised care than women in control groups.

The Two-County trial provides the best evidence that factors other than mammography screening influenced breast cancer mortality. Besides mammography screening, the intervention also encompassed enhancing breast cancer awareness, breast self-examination and rapid referral of women presenting at screening with breast symptoms, all factors that would have, according to investigators, reduced

patient delay and led to earlier detection of interval cancers and their treatment.[28] In addition, the Two-County trial randomised women by geographical cluster, each cluster comprising about 2700 women in Dalarna (Kopparberg) county and about 3200 women in Östergötland county.[13] This large cluster randomisation scheme is likely to have exacerbated differences between screening and control groups with respect to information, awareness and medical management. Finally, some data indicate different management of breast cancer patients according to randomisation group: the histological grade of cancers found during the Two-County trial was unknown for 19% of patients in the control group vs. 10% in the screening group ($p < 0.0001$).[13] Lymph node status was missing for 5.0% of patients in the screening group and 7.3% of patients in the control group ($p = 0.0396$).[13]

It seems likely that Swedish trials have departed from the 'ceteris paribus' principle by which an experiment evaluating the effect of one action must make sure that all other things remain equal and will not interfere with study results.

In contrast, the Canadian trials that found no reduction in the risk of breast cancer death associated with mammography screening, adopted the typical parallel group randomised trial design. All enrolled women were volunteers who signed an informed consent form before randomisation and received the same information and medical attention.[10]

A second reason for the persistent lower risk of breast cancer death for cancers found in the intervention and post-intervention periods could be biased attribution of causes of death. Of the eight major breast screening trials, only the Health Insurance Plan and the Canadian trial implemented endpoint committees unaware of the screening status of deceased women. In left-to-nature trials, health professionals completing death certificates of being part of local endpoint committees may have known or guessed which women have been invited to screening but had no idea regarding women allocated to control groups. To circumvent this problem, the overview of 2002 used death certificates for cause of death assessment because the overview of 1993 found that causes reported on certificates correlated well with causes established by an independent endpoint committee that had access to all medical and necropsy information.[1] However, in the 2002 overview, there were nearly twice as many breast cancer deaths for the Malmö, Östergötland, Stockholm and Goteborg trials than in the 1993 overview,[29] and it is unknown up to which point the reliability of death certificates was maintained over time.

In conclusion, unconventional computation of the relative risk of breast cancer death impacted on the reported results of the Swedish trials on mammography screening. This led to an intrinsic bias in favour of screening. If calculations of relative risks had been carried out using similar methodological approaches to other cancer screening trials conducted in the more recent era, the Swedish trials would not have found a 20% reduction of breast cancer death due to mammography screening. This conclusion can be verified through a reanalysis of Swedish trial original data according to methods used in other cancer screening trials.

Declarations

Competing interests: None declared

Funding: This research was funded by the International Prevention Research Institute (iPRI), Lyon, France.

Ethical approval: Not required because of the use of data extracted from published articles.

Guarantor: PA

Contributorship: PA was responsible for the study design and study coordination. PA and MS undertook the literature search. PA, MB and MS were responsible for the figures and data extraction. The data analysis was done by PA and MB. All co-authors participated in the data interpretation. PA wrote the first version of the article and PA, RS and PB finalised the article submitted to the journal.

Acknowledgements: None

Provenance: Not commissioned; peer-reviewed by Klim McPherson

References

1. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B and Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *Lancet* 2002; 359: 909–919.
2. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM and Chen TH. The randomized trials of breast cancer screening: what have we learned? *Radiol Clin North Am* 2004; 42: 793–806, v.
3. Autier P, Boniol M, Middleton R, Dore JF, Hery C, Zheng T, et al. Advanced breast cancer incidence following population-based mammographic screening. *Ann Oncol* 2011; 22: 1726–1735.
4. de Glas NA, de Craen AJ, Bastiaannet E, Op 't Land EG, Kiderlen M, van de Water W, et al. Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. *BMJ* 2014; 349: g5410.
5. Bleyer A and Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. *N Engl J Med* 2012; 367: 1998–2005.
6. Sigurdsson K and Sigvaldason H. Effectiveness of cervical cancer screening in Iceland, 1964–2002: a study on trends in incidence and mortality and the effect of risk factors. *Acta Obstet Gynecol Scand* 2006; 85: 343–349.

7. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer* 2010; 116: 544–573.
8. Scholefield JH, Moss SM, Mangham CM, Whynes DK and Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. *Gut* 2012; 61: 1036–1040.
9. Miller AB. Screening for breast cancer with mammography. *Lancet* 2001; 358: 2164; author reply 2167–2168.
10. Miller AB, Wall C, Baines CJ, Sun P, To T and Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. *BMJ* 2014; 348: g366.
11. Holmberg L, Duffy SW, Yen AM, Tabar L, Vitak B, Nystrom L, et al. Differences in endpoints between the Swedish W-E (two county) trial of mammographic screening and the Swedish overview: methodological consequences. *J Med Screen* 2009; 16: 73–80.
12. Moss SM, Cuckle H, Evans A, Johns L, Waller M and Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. *Lancet* 2006; 368: 2053–2060.
13. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A and Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. *Radiol Clin North Am* 1992; 30: 187–210.
14. Frisell J, Lidbrink E, Hellstrom L and Rutqvist LE. Folluwup after 11 years - update of mortality results in the Stockholm mammographic screening trial. *Breast Cancer Res Treat* 1997; 45: 263–270.
15. Andersson I and Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo Mammographic Screening Program. *J Natl Cancer Inst Monogr* 1997; 22: 63–67.
16. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, et al. The Gothenburg breast screening trial. *Cancer* 2003; 97: 2387–2396.
17. Tabar L, Fagerberg G, Day NE, Duffy SW and Kitchin RM. Breast cancer treatment and natural history: new insights from results of screening. *Lancet* 1992; 339: 412–414.
18. Frisell J, Lidbrink E, Hellstrom L and Rutqvist LE. Followup after 11 years–update of mortality results in the Stockholm mammographic screening trial. *Breast Cancer Res Treat* 1997; 45: 263–270.
19. Frisell J, Eklund G, Hellstrom L, Lidbrink E, Rutqvist LE and Somell A. Randomized study of mammography screening–preliminary report on mortality in the Stockholm trial. *Breast Cancer Res Treat* 1991; 18: 49–56.
20. Tabar L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. *Radiology* 2011; 260: 658–663.
21. Zackrisson S, Andersson I, Janzon L, Manjer J and Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. *BMJ* 2006; 332: 689–692.
22. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B and Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *Lancet* 2002; 359: 909–919.
23. Berry DA. Benefits and risks of screening mammography for women in their forties: a statistical appraisal. *J Natl Cancer Inst* 1998; 90: 1431–1439.
24. Bjurstam N and Bjorneld L. Author reply to AB Miller et al. RE The Gothenburg breast screening trial. *Cancer* 1998; 83: 188–190.
25. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. *BMJ* 1988; 297: 943–948.
26. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health insurance plan. *J Natl Cancer Inst Monogr* 1997; 22: 27–30.
27. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. *Lancet* 1985; 1: 829–832.
28. Tabar L, Akerlund E and Gad A. Five-year experience with single-view mammography randomized controlled screening in Sweden. *Recent Results Cancer Res* 1984; 90: 105–113.
29. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Rydén S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. *Lancet* 1993; 341: 973–978.